We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+87.55%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.13B
AUM Growth
+$1.97B
(+62%)
Cap. Flow
+$788M
Cap. Flow
% of AUM
15.36%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$391M |
| 2 |
Novavax
NVAX
|
+$182M |
| 3 |
Vaxcyte
PCVX
|
+$177M |
| 4 |
Legend Biotech
LEGN
|
+$97M |
| 5 |
MacroGenics
MGNX
|
+$79.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$233M |
| 2 |
Exelixis
EXEL
|
+$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$44.1M |
| 4 |
Gilead Sciences
GILD
|
+$41M |
| 5 |
Relmada Therapeutics
RLMD
|
+$22.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARYBU
51
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $8.12M | 0.16% |
+700,000
| New | +$7.69M |
|
|
GRTX
52
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $5.89M | 0.11% |
825,118
-67,997
| -8% | -$722K |
|
|
EPIX
53
DELISTED
ESSA Pharma
EPIX
| $5.27M | 0.1% |
849,300
-110,000
| -11% | -$522K |
|
54
X4 Pharmaceuticals
XFOR
$377M
| $5.21M | 0.1% |
18,650
-1,426
| -7% | -$390K |
|
55
Insmed
INSM
$21.1B
| $2.41M | 0.05% |
87,405
| – | – |
|
56
Ovid Therapeutics
OVID
$424M
| $2.1M | 0.04% |
+285,000
| New | +$1.33M |
|
57
Cartesian Therapeutics
RNAC
$229M
| $270K | 0.01% |
3,167
-25,854
| -89% | -$2.34M |
|
58
Compugen
CGEN
$209M
| – | – |
-2,957,434
| Closed | -$21.5M |
|
|
59
Exelixis
EXEL
$13.5B
| – | – |
-4,524,961
| Closed | -$77.9M |
|
|
60
Gilead Sciences
GILD
$161B
| – | – |
-548,000
| Closed | -$41M |
|
61
NovoCure
NVCR
$1.82B
| – | – |
-259,099
| Closed | -$17.4M |
|
62
uniQure
QURE
$3.04B
| – | – |
-82,180
| Closed | -$3.9M |
|
63
Vericel Corp
VCEL
$2.41B
| – | – |
-100,000
| Closed | -$917K |
|
|
IMGN
64
DELISTED
Immunogen Inc
IMGN
| – | – |
-5,166,303
| Closed | -$17.6M |
|
|
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-429,399
| Closed | -$3.06M |
|
|
RARX
66
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-4,858,260
| Closed | -$233M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, RA Capital Management held 66 positions worth $5.13B, up 62% from $3.17B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $788M of net new capital in Q2 2020, opening 18 new positions and adding to 9 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier.
On the sell side, the largest reduction was Zogenix, Inc., an estimated $44.1M trimmed.
- RA Capital Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
- RA Capital Management added most to TG Therapeutics in Q2 2020, an estimated $38.7M increase.
- RA Capital Management's biggest Q2 2020 reduction was Zogenix, Inc., cutting an estimated $44.1M.
- RA Capital Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $233M.
- RA Capital Management's ten largest holdings make up 55% of its $5.13B portfolio in Q2 2020.
- RA Capital Management opened 18 new positions and closed 9 in Q2 2020.
- RA Capital Management's portfolio value rose 62% quarter-over-quarter to $5.13B.
Based on RA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.